Research programme: melanocortin 4 receptor agonists - Palatin Technologies/AstraZeneca

Drug Profile

Research programme: melanocortin 4 receptor agonists - Palatin Technologies/AstraZeneca

Alternative Names: PT 15

Latest Information Update: 23 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; Palatin Technologies
  • Developer Palatin Technologies
  • Class Metals; Peptides; Small molecules
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Metabolic syndrome; Obesity

Most Recent Events

  • 09 Feb 2017 Preclinical development in Diabetes mellitus, Metabolic syndrome and Obesity is ongoing in USA
  • 29 Sep 2015 Palatin terminates its research collaboration and license agreement with AstraZeneca for melanocortin 4 receptor agonists in USA
  • 11 Dec 2008 Palatin and AstraZeneca extend their research collaboration and licensing agreement for compounds targeting melanocortin receptors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top